Skip to main content
Figure 7 | Cardiovascular Diabetology

Figure 7

From: Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice

Figure 7

Effect of long-term empagliflozin treatment on cardiac interstitial fibrosis (A), peri-coronary arterial fibrosis and coronary arterial thickening (B), cardiac macrophage infiltration (C) and cardiac superoxide (D) in db/db mice. Upper panels in (A) and (B) indicate representative photomicrographs of cardiac sections stained with Sirius red. Upper panels in (C) and (D) indicate representative photomicrographs of cardiac sections stained with CD68 antibody and dihydroethidium, respectively. Abbreviations used are the same as in Figure 5. *p < 0.05, *p < 0.01 vs control db/db mice. Values are mean ± SEM (n = 9-11). Bar = 100 μm in (A), (C), and (D). Bar = 50 μm in (B).

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840